Evercore acquires Robey Warshaw for £146 million —
Evercore’s acquisition of London-based boutique advisory Robey Warshaw marks a significant escalation in the battle for high-end M&A mandates. The $196 million deal provides Evercore with direct access to elite UK boardrooms and succession-ready leadership — at a time when US banks are aggressively growing local teams.
Robey Warshaw, founded by investment banking heavyweights, has long punched above its weight on the City’s largest deals. With succession pressure mounting among boutique founders, the sale underscores ongoing consolidation in independent advisory, as scale and client access become ever more valuable.
Brookfield agrees £2.4bn Just Group takeover —
Canadian investment giant Brookfield’s £2.4 billion offer for Just Group is the latest chapter in the accelerating consolidation of UK life insurance and pension providers. Private capital continues to be drawn to the stable, cash-generative profile of UK pension risk transfer businesses, with regulatory change and demographic trends creating long-term demand.
Brookfield will merge Just with its UK annuities platform, Blumont, but keep the existing management and brand in place. The move echoes the recent Apollo-backed £5.7 billion Pension Insurance Corporation deal, as alternative asset managers target the sector for its steady returns and scale opportunities.
Hammerson takes full control of Bullring & Grand Central —
Hammerson’s £319 million acquisition of the remaining 50% stake in Birmingham’s Bullring & Grand Central shopping centre signals renewed confidence in prime UK retail property. After years of pandemic-driven disruption and falling valuations, asset managers are again consolidating high-footfall, city-centre sites.
Hammerson is funding the deal through a £140 million share placing, while suspending its buyback programme. The move marks a turning point for city-centre retail and illustrates a broader stabilisation in the commercial property sector, even as financing remains selective.
Müller buys Biotiful Gut Health for £115 million —
German dairy giant Müller’s acquisition of Biotiful Gut Health is the latest sign of the UK’s booming functional foods sector. Biotiful, the UK’s kefir leader, has enjoyed rapid growth on the back of shifting consumer health trends and now commands around 70% of the local kefir market.
For Müller, the move represents a strategic pivot toward “wellness” brands and higher-growth categories, as traditional dairy faces margin pressures. The deal also highlights growing competition for innovative FMCG assets and the desire among global strategics to future-proof their portfolios.
Merck to buy Verona Pharma for $10 billion —
Merck’s $10 billion acquisition of UK-based Verona Pharma demonstrates the enduring international appetite for British life sciences. With big pharma searching for innovative late-stage assets to replenish their pipelines, UK biotech remains a major draw.
Verona’s key asset, Ohtuvayre (ensifentrine), targets respiratory diseases — an area of strong global demand. Merck’s move highlights the continued relevance of the UK’s science base, even as early-stage funding conditions remain challenging.
Bottom line —
A closer look at this week’s landmark UK deals reveals not just a cluster of high-profile transactions, but a set of moves that map the evolving priorities of both global investors and domestic strategics. Rather than signalling a single dominant narrative, these acquisitions reflect how UK assets are being revalued, repurposed, and repositioned in response to changing sector dynamics and shifting international flows.
International buyers, from Evercore to Merck and Brookfield, are zeroing in on the UK’s structural advantages: unrivalled advisory talent, innovative consumer brands, and a mature insurance and biotech landscape. Evercore’s pursuit of Robey Warshaw, for example, highlights the premium now placed on deep local networks and relationship-driven mandates, especially as succession questions prompt consolidation among elite City boutiques. Meanwhile, Müller’s and Hammerson’s acquisitions show domestic corporates leaning into higher-growth, consumer-driven segments as part of a broader recalibration post-pandemic.
On the listed company side, private equity and global strategics remain alert to persistent valuation gaps on the LSE, as seen with Brookfield’s and Merck’s headline-grabbing offers. These moves signal both a bid for scale and a confidence in the UK’s capacity for long-term value creation, even in an environment shaped by regulatory uncertainty and evolving market conditions.
Key takeaways —
- Global capital is accelerating UK market consolidation: From Evercore to Brookfield, international players are deploying long-term capital to secure access, scale, and sector leadership in the UK.
- Strategic pivots are driving deal logic: Domestic champions like Müller and Hammerson are reshaping their core businesses to anticipate shifting consumer trends and post-pandemic realities.
- Sector fundamentals remain the key catalyst: Deals reflect deeper trends — succession in advisory, functional food growth, annuity demand, retail stabilisation, and biotech innovation — as UK M&A adapts to a changing landscape.
Stay ahead of the curve with Business Quarter’s weekly M&A briefing, a concise, authoritative roundup of the biggest deals, strategic plays, and market-moving partnerships.
Sign up now to get each week’s summary straight to your inbox.
